Editorial method
Keep the treatment
and the evidence together.
Read how we distinguish provider advertising from clinical evidence, approved products from off-label uses and current labels from older summaries.
Begin with the treatment goal
We identify whether a source concerns hot flashes, another symptom or an outcome measured in a particular study. Approval for one indication does not establish a benefit for every menopause concern. We preserve those limits when presenting a medicine or behavioral approach.
Name the exact product
A product’s strength, form, manufacturer and approval record matter. An ingredient-level description cannot establish all of them. We distinguish an approved product used off-label from a preparation whose finished-product identity is unknown, and avoid assuming compounding when the source does not state it.
Check the current record
The publication date and source-check date identify this edition. We examine current labeling alongside guidance and regulator summaries. An older position statement or original approval snapshot may omit later products or safety changes; its date remains part of its interpretation.
Make uncertainty useful
When a commercial page does not establish the full charge, prescribing arrangement, pharmacy or treatment-specific checkout, we say what remains unresolved. We do not interpret an advertised starting price as a personal invoice or a completed care experience.
Disclose first position
CoreAge is our first commercial feature through the publication’s promotional relationship. The placement does not settle a clinical comparison. Provider reviews describe advertised access and terms without inventing patient outcomes, independent scores or treatment superiority.
Research is not clinical sign-off
The editorial byline identifies organizational document research. Source checking and review do not create a clinician endorsement. We do not provide personal doses, treatment switches or monitoring schedules; those decisions require the responsible care team.